ERBB2 and breast cancer: We did not observe any significant difference in terms of DFI, PFI, and OS when comparing HER2-low tumors with non-HER-low BCs, and this is reassuring for clinical practice, considering that patients with HER2-low BC likely did not receive any HER2-targeting therapy.